Theranos Indirect Investors Denied Class Cert. For Fraud Suit
A California federal judge on Thursday refused to certify a group of indirect investors alleging securities fraud claims against the once high-flying blood testing company Theranos Inc., finding that weaknesses in...To view the full article, register now.
Already a subscriber? Click here to view full article